| Therapeutic | Daclizumab |
| Target | IL2RA |
| Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS |
| Light Chain | DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK |
| 100% seqID Fv Structure | 3nfs%3AHL%2F3nfp%3AHL%3AAB [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3nfs%3AHL%2F3nfp%3AHL%3AAB [Fvs: ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | GS Gene Expression System |
| INN Year Proposed | 1994 |
| INN Year Recommended | 1998 |
| Companies Involved | AbbVie%3BBiogen%3BDana-Farber Cancer Institute%3BNational Cancer Institute %28USA%29%3BPDL BioPharma |
| Conditions Approved | Renal transplant rejection |
| Conditions Active | Multiple sclerosis |
| Conditions Discontinued | Asthma%3BGraft-versus-host disease%3BHaematological malignancies%3BImmune-mediated uveitis%3BLiver transplant rejection%3BPsoriasis%3BTropical spastic paraparesis%3BType 1 diabetes mellitus%3BUlcerative colitis |
| Notes | Daclizumab is the new name for Dacliximab %28PL78%29 |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
